Establishes Prescription Drug Affordability Board in Department of Consumer and Business Services to review prices for nine drugs and at least one insulin product, from among drugs reported to Prescription Drug Price Transparency program by prescription drug manufacturers, drugs reported by insurers in filings and insulin drugs marketed in this state, that are expected to create affordability challenges for health systems or high out-of-pocket costs for patients in Oregon based on specified criteria.